MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Danaher Corp

Ouvert

SecteurSoins de santé

196.17 0.53

Résumé

Variation du prix de l'action

24h

Actuel

Min

192.84

Max

197.06

Chiffres clés

By Trading Economics

Revenu

268M

1.1B

Ventes

738M

6.5B

P/E

Moyenne du Secteur

34.964

57.333

BPA

2.14

Rendement du dividende

0.69

Marge bénéficiaire

16.611

Employés

61,000

EBITDA

-230M

1.4B

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+22.75% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.69%

2.63%

Prochains Résultats

22 juil. 2025

Date du Prochain Dividende

25 avr. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-29B

134B

Ouverture précédente

195.64

Clôture précédente

196.17

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Danaher Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 avr. 2025, 10:34 UTC

Résultats

Danaher 1Q Results Decline But Top Estimates

5 févr. 2025, 12:54 UTC

Résultats

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

29 janv. 2025, 11:44 UTC

Résultats

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

22 oct. 2024, 10:35 UTC

Résultats

Danaher 3Q EPS, Sales Top Views on Strong Cepheid Test Demand

22 avr. 2025, 10:02 UTC

Résultats

Danaher Still Sees 2025 Adjusted Core Revenue Up About 3% >DHR

22 avr. 2025, 10:02 UTC

Résultats

Danaher Sees 2025 Adj EPS $7.60-Adj EPS $7.75 >DHR

22 avr. 2025, 10:02 UTC

Résultats

Danaher Sees 2Q Adjusted Core Revenue Up Low-Single Digits >DHR

22 avr. 2025, 10:01 UTC

Résultats

Danaher: Macro Backdrop Has Become More Dynamic Since Start of Year >DHR

22 avr. 2025, 10:01 UTC

Résultats

Danaher 1Q Adjusted Core Revenue Flat >DHR

22 avr. 2025, 10:00 UTC

Résultats

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

22 avr. 2025, 10:00 UTC

Résultats

Danaher 1Q Adj EPS $1.88 >DHR

22 avr. 2025, 10:00 UTC

Résultats

Danaher 1Q EPS $1.32 >DHR

22 avr. 2025, 10:00 UTC

Résultats

Danaher 1Q Sales $5.74B >DHR

22 avr. 2025, 10:00 UTC

Résultats

Danaher 1Q Net $954M >DHR

29 janv. 2025, 15:25 UTC

Market Talk
Résultats

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

29 janv. 2025, 13:56 UTC

Actualités
Résultats

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

29 janv. 2025, 11:08 UTC

Résultats

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

29 janv. 2025, 11:07 UTC

Résultats

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

29 janv. 2025, 11:07 UTC

Résultats

Danaher: Expect to Return to Growth, Build Back to Normal Market Conditions in 2025 >DHR

29 janv. 2025, 11:02 UTC

Résultats

Danaher Sees 2025 Adjusted Core Revenue Up About 3% >DHR

29 janv. 2025, 11:01 UTC

Résultats

Danaher Sees 1Q Adjusted Core Revenue Down Low-Single Digits >DHR

29 janv. 2025, 11:01 UTC

Résultats

Danaher 4Q Operating Cash Flow $2B, Free Cash Flow $1.5B >DHR

29 janv. 2025, 11:00 UTC

Résultats

Danaher 4Q Adjusted Core Revenue Rose 1% >DHR

29 janv. 2025, 11:00 UTC

Résultats

Danaher 4Q Cont Ops EPS $1.49 >DHR

29 janv. 2025, 11:00 UTC

Résultats

Danaher 4Q Net $1.09B >DHR

29 janv. 2025, 11:00 UTC

Résultats

Danaher 4Q EPS $1.49 >DHR

29 janv. 2025, 11:00 UTC

Résultats

Danaher 4Q Adj EPS $2.14 >DHR

29 janv. 2025, 11:00 UTC

Résultats

Danaher 4Q Sales $6.5B >DHR

22 oct. 2024, 10:02 UTC

Résultats

Danaher 3Q Adjusted Core Revenue Rose 0.5% >DHR

22 oct. 2024, 10:02 UTC

Résultats

Danaher Still Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

Comparaison

Variation de prix

Danaher Corp prévision

Objectif de Prix

By TipRanks

22.75% hausse

Prévisions sur 12 Mois

Moyen 241.2 USD  22.75%

Haut 265 USD

Bas 210 USD

Basé sur 18 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

18 ratings

15

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

190.1 / 205.11Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.